Business Context and Reporting Period
Organon & Co. filed a Current Report on Form 8-K on July 31, 2026, to disclose financial results for the quarter ended June 30, 2026. The filing references the concurrent submission of the Quarterly Report on Form 10-Q. The Company noted that its customary practice of issuing a quarterly earnings press release and hosting an earnings conference call has been suspended due to a pending merger with Sun Pharmaceutical Industries Limited.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing serves as a regulatory notice that supplemental non-GAAP financial metrics for the quarter ended June 30, 2026, are available in Exhibit 99.1 attached to this report and incorporated by reference. Investors are directed to the Form 10-Q for full GAAP financial statements.
Material Changes
The filing does not detail specific material changes in financial performance versus prior periods. The primary operational change disclosed is the suspension of standard earnings communications (press releases and conference calls) in light of the pending merger with Sun Pharmaceutical Industries Limited.
Guidance, Outlook, and Risks
The document states that the Current Report and Exhibit 99.1 contain forward-looking statements regarding the Company. It includes a cautionary statement identifying important factors that could cause actual results to differ materially from anticipated results. No specific guidance or outlook figures are provided in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 of this filing for the specific supplemental non-GAAP financial metrics for the quarter ended June 30, 2026.
- Access the Form 10-Q filed on July 31, 2026, for complete GAAP financial statements and detailed performance data.
- Monitor updates regarding the status and timeline of the pending merger with Sun Pharmaceutical Industries Limited.
- Verify the specific forward-looking risk factors detailed in the attached exhibits that may impact future results.